GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (MEX:AGIO) » Definitions » Cyclically Adjusted Price-to-FCF

Agios Pharmaceuticals (MEX:AGIO) Cyclically Adjusted Price-to-FCF : (As of Sep. 27, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Agios Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agios Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Agios Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Agios Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Agios Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Agios Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Agios Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-23.462/132.5538*132.5538
=-23.462

Current CPI (Jun. 2024) = 132.5538.

Agios Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 -8.841 100.428 -11.669
201412 -3.889 99.070 -5.203
201503 -12.036 99.621 -16.015
201506 -2.901 100.684 -3.819
201509 -12.666 100.392 -16.724
201512 -14.936 99.792 -19.839
201603 -9.794 100.470 -12.922
201606 75.565 101.688 98.501
201609 -26.312 101.861 -34.240
201612 -25.664 101.863 -33.397
201703 -33.118 102.862 -42.678
201706 -23.210 103.349 -29.769
201709 -29.861 104.136 -38.010
201712 -30.481 104.011 -38.846
201803 -32.761 105.290 -41.244
201806 -23.406 106.317 -29.182
201809 -21.588 106.507 -26.868
201812 -25.385 105.998 -31.745
201903 -34.947 107.251 -43.192
201906 -29.251 108.070 -35.878
201909 -29.419 108.329 -35.998
201912 -29.558 108.420 -36.137
202003 -37.442 108.902 -45.574
202006 -24.081 108.767 -29.347
202009 -23.454 109.815 -28.311
202012 -14.346 109.897 -17.304
202103 -35.789 111.754 -42.450
202106 -38.315 114.631 -44.305
202109 -30.695 115.734 -35.156
202112 -33.483 117.630 -37.731
202203 -36.694 121.301 -40.098
202206 -27.958 125.017 -29.644
202209 -26.183 125.227 -27.715
202212 -23.512 125.222 -24.889
202303 -31.175 127.348 -32.449
202306 -20.579 128.729 -21.190
202309 -24.819 129.860 -25.334
202312 -22.072 129.419 -22.607
202403 -29.437 131.776 -29.611
202406 -23.462 132.554 -23.462

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Agios Pharmaceuticals  (MEX:AGIO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Agios Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals Business Description

Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.